LiGalli

LiGalli is an early-stage biotech innovator developing an intelligent, connected intravaginal ring (the MedRing) for personalized drug delivery and health monitoring. The company's platform technology combines a physical device, a smartphone companion app, and a cloud data platform to enable precise dosing, improve patient compliance, and collect valuable health data. Initially targeting conditions like overactive bladder, LiGalli is positioning itself at the intersection of women's health, digital therapeutics, and smart medical devices, with a vision to create more tailored and effective treatments.

The MedRing Platform: an integrated system featuring a programmable intravaginal ring for scheduled drug delivery and biometric monitoring, a patient smartphone app for control and tracking, and a cloud data platform for secure health data storage and sharing.

Competition includes traditional oral therapies, existing passive intravaginal rings (e.g., for contraception/hormone therapy), and emerging smart drug delivery systems from other startups. LiGalli's differentiation lies in its programmability, multi-drug platform potential, and integrated data monitoring capabilities.